Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.

In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.

On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.

Ikena, Senti and others look to clinical presentations at AACR.

The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.

Skyscraper-01 stars at AACR's upcoming clinical trial plenary.

After Astra's EsoBiotec takeover the battle for uniqueness begins.

While Sutro shows why it’s shelved luvelta-T.

The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.